• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Belimumab after rituximab reduces risk for severe flare in systemic lupus erythematosus

byBoaz WongandHarsh Shah
November 15, 2021
in Chronic Disease, Dermatology, Rheumatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Belimumab combined with rituximab was shown to significantly reduce IgG anti-dsDNA antibody levels in patients with systemic lupus erythematosus.

2. Belimumab following rituximab therapy was shown to reduce severe flares in patients with systemic lupus erythematosus.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Rituximab, an anti-CD20 antibody therapy, is used to deplete B-cells in patients with systemic lupus erythematosus (SLE) who don’t respond to conventional immunosuppressive therapy. However, this treatment regimen increases B-cell activating factor (BAFF) neutralizing antibody levels, leading to increased IgG anti-dsDNA antibodies, which have been suspected to cause flares. Therefore, this study investigated the inhibition of BAFF-neutralizing antibodies with belimumab to improve therapeutic outcomes. The study determined patients receiving belimumab had significantly reduced serum levels of anti-dsDNA antibodies and reduced frequency of severe flares compared to the placebo group. Both groups experienced similar frequencies of severe adverse events. The study was limited by the small sample size and the lack of an outcome-oriented primary endpoint. While the significant reduction in anti-dsDNA antibody levels is clear, further investigation is required to correlate its clinical impact. Overall, the study supports the continued investigation of belimumab in combination with rituximab for first-line or refractory treatment of SLE.

Click to read the study in Annals of Internal Medicine

Relevant Reading: The BAFFling effects of rituximab in lupus: danger ahead?

In-Depth [randomized controlled trial]: In this multi-center, double-blind, placebo-controlled, randomized controlled trial known as BEAT-LUPUS, 52 patients participated from 16 centers in the United Kingdom. Participants between 18 to 75 years of age, diagnosed with stage IV systemic lupus erythematosus (SLE), and had a positive anti-dsDNA antibody test within the last five years were included in the study. Participants who had not failed conventional therapy were excluded from the study. The participants were randomized in a 1:1 ratio to receive either one receiving intravenous 10mg/kg belimumab four to eight weeks after rituximab therapy or placebo treatment, respectively. The primary outcome was serum levels of IgG anti-dsDNA antibodies detected by enzyme-linked immunosorbent assay after 52 weeks. Belimumab therapy significantly reduced the serum levels of anti-dsDNA antibodies compared to the placebo group (P < 0.001). These experimental patients achieved a 71% (95% confidence interval [CI], 58% to 81%) greater reduction in IgG anti-dsDNA antibody levels relative to baseline compared to the placebo group. Moreover, patients receiving belimumab experienced 73% fewer severe flares (hazard ratio, 0.27; 95% CI, 0.07 to 0.98; P = 0.033); however, when moderate flares were also accounted for, significance was lost (P = 0.124). No difference in severe adverse events was found between the two groups with depressive symptoms being common. Taken altogether, this study supports the further investigation of combinational rituximab and belimumab therapy for the treatment of SLE as first-line or in refractory patients to conventional therapy.

RELATED REPORTS

#VisualAbstract: Odronextamab shows promising clinical activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

Iberdomide elicits SRI-4 response in patients with systemic lupus erythematosus

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: anti-CD20 antibodyanti-dsDNA antibodybelimumabrituximabsystemic lupus erythematosus (SLE)
Previous Post

Adequate antibody response to mRNA-1273 COVID-19 vaccine occurs in patients with cancer

Next Post

Noncontrast CT vs CT Perfusion or MRI selection in late presentation of large-vessel–occlusion stroke

RelatedReports

#VisualAbstract: Odronextamab shows promising clinical activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
StudyGraphics

#VisualAbstract: Odronextamab shows promising clinical activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

April 23, 2022
#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia
StudyGraphics

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

April 8, 2022
Multidrug induction therapy increases remission from lupus nephritis
Chronic Disease

Iberdomide elicits SRI-4 response in patients with systemic lupus erythematosus

March 21, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Oncology

Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics

February 22, 2022
Next Post
Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial

Noncontrast CT vs CT Perfusion or MRI selection in late presentation of large-vessel–occlusion stroke

Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors

Physical activity interventions may improve symptoms of attention-deficit/hyperactivity disorder  

#VisualAbstract: High-dose glucocorticoids may be detrimental for the management of patients with advanced melanoma expieriencing immune-related adverse events

#VisualAbstract: High-dose glucocorticoids may be detrimental for the management of patients with advanced melanoma expieriencing immune-related adverse events

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.